NERM
PCRX icon

New England Research & Management’s Pacira BioSciences PCRX Stock Holding History

New England Research & Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,110
Closed -$546K – 172
2015
Q4 		$546K Sell
7,110
-2,350
-25% -$133K 0.47% 77
2015
Q3 		$389K Sell
9,460
-300
-3% -$18.4K 0.37% 100
2015
Q2 		$690K Buy
9,760
+6,360
+187% +$501K 0.57% 68
2015
Q1 		$302K Buy
+3,400
New +$345K 0.26% 130

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

New England Research & Management's PCRX Position: Q1 2016 in Review

New England Research & Management sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 7,110 shares — an estimated $546K sold.

New England Research & Management first reported a position in PCRX in Q1 2015 and held it in 4 quarters. The position peaked at $690K in Q2 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

  • New England Research & Management reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
  • New England Research & Management sold 7,110 Pacira BioSciences shares in Q1 2016, an estimated $546K.
  • New England Research & Management first reported a position in Pacira BioSciences in Q1 2015 and held it in 4 quarters.
  • New England Research & Management's Pacira BioSciences position peaked at $690K in Q2 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on New England Research & Management's 13F filing for Q1 2016, filed 6 Apr 2016.